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Abstract
Background: Anxiety and depression are common among patients attending cardiac rehabilitation services.
Currently available pharmacological and psychological interventions have limited effectiveness in this population.
There are presently no psychological interventions for anxiety and depression integrated into cardiac rehabilitation
services despite emphasis in key UK National Health Service policy. A new treatment, metacognitive therapy, is
highly effective at reducing anxiety and depression in mental health settings. The principal aims of the current
study are (1) to evaluate the acceptability of delivering metacognitive therapy in a home-based self-help format
(Home-MCT) to cardiac rehabilitation patients experiencing anxiety and depressive symptoms and conduct a
feasibility trial of Home-MCT plus usual cardiac rehabilitation compared to usual cardiac rehabilitation; and (2) to
inform the design and sample size for a full-scale trial.
Methods: The PATHWAY Home-MCT trial is a single-blind feasibility randomised controlled trial comparing usual
cardiac rehabilitation (control) versus usual cardiac rehabilitation plus home-based self-help metacognitive therapy
(intervention). Economic and qualitative evaluations will be embedded within the trial. Participants will be assessed
at baseline and followed-up at 4 and 12 months. Patients who have been referred to cardiac rehabilitation
programmes and have a score of ≥ 8 on the anxiety and/or depression subscales of the Hospital Anxiety and
Depression Scale will be invited to take part in the study and written informed consent will be obtained.
Participants will be recruited from the National Health Service in the UK. A minimum of 108 participants will be
randomised to the intervention and control arms in a 1:1 ratio.
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Discussion: The Home-MCT feasibility randomised controlled trial will provide evidence on the acceptability of
delivering metacognitive therapy in a home-based self-help format for cardiac rehabilitation patients experiencing
symptoms of anxiety and/or depression and on the feasibility and design of a full-scale trial. In addition, it will
provide provisional point estimates, with appropriately wide measures of uncertainty, relating to the effectiveness
and cost-effectiveness of the intervention.
Trial registration: ClinicalTrials.gov, NCT03129282, Submitted to Registry: 11 April 2017.
Keywords: Metacognitive therapy, Rumination, Worry, Anxiety, Depression, Cardiac rehabilitation, Self-help, Home
therapy, Psychological intervention, Heart disease
Background
There is strong evidence demonstrating that anxiety and
depressive symptoms are common among heart disease
patients [1–5]. In addition, the European Association of
Preventive Cardiology has emphasised that symptoms of
anxiety and depression in heart disease patients play a
key role in the success of cardiovascular rehabilitation
(CR) programmes [6]. Anxiety and depression are asso-
ciated with lower rates of adherence to treatment, a
higher prevalence of high-risk behaviours (e.g. smoking),
and increased risk of further cardiac events and mortal-
ity [3, 7–11]. Specifically, a meta-analysis found that de-
pression is a risk factor for mortality in heart disease
patients [12], and anxiety and depressive symptoms pre-
dicted mortality in percutaneous coronary intervention
patients at a 10-year follow-up [13]. Furthermore, two
recent studies in this population found that anxiety and
depression predicted future symptoms of emotional dis-
tress, higher rates of hospital readmissions, higher costs
to the healthcare system, lower quality of life, and poorer
prognosis [14, 15]. Consequently, it is crucial to identify
and treat symptoms of anxiety and depression effectively
to ensure that CR programmes have better clinical out-
comes, improve the quality of life of heart disease pa-
tients, and reduce health service costs.
In 2010, the Department of Health implemented the
CR commissioning pack to improve cost-effectiveness in
CR services [16], and more recently the European Asso-
ciation for Preventive Cardiology issued details of the
core components and standards for secondary preven-
tion in the clinical management of patients with cardio-
vascular diseases [6]. Both include comprehensive
service specifications where psychological assessment
and support are advocated throughout [6, 16], specific-
ally assessment of patients’ psychological needs, includ-
ing anxiety and depression, and interventions targeting
them, using evidence-based approaches. Both organisa-
tions further advocate that such comprehensive CR pro-
grammes should be delivered by appropriately trained
professionals [6, 16]. CR programmes aim to facilitate
recovery after a heart event, promote healthy behaviours,
improve lifestyle risk factors, reduce the risk of further
related problems, and improve patients’ emotional
wellbeing (e.g. anxiety, depression) and health-related
quality of life. CR programmes are usually delivered
as centre-based group programmes in hospital or
community settings [16]. In a survey of CR services
in 28 European countries, two thirds of countries re-
ported a 30% or lower provision of an outpatient
(Phase II) CR programme [17]. In the UK, 49% of re-
ferred patients decline participation [18], with lower
uptake and adherence in certain groups including
people experiencing emotional distress [19].
Home-based programmes have been introduced to
widen access and participation in CR. Two
home-based self-help packages have been successfully
integrated into CR programmes into the National
Health Service (NHS) [20], the Heart Manual [21]
and the Angina Plan (www.anginaplan.org.uk) [22].
These programmes include a manual that patients
complete at home and are facilitated by trained healthcare
professionals either face-to-face or by telephone. Both
home-based approaches follow the CR commissioning
pack guidelines and comprise a number of components,
including education about heart disease, medication and
dietary recommendations, an exercise/activity plan, life-
style change advice, information and strategies to manage
anxiety and depression, and a relaxation CD. These two
home-based self-help packages are utilised by over 20,000
heart disease patients annually in the UK, and there is an
increasing trend towards self-help approaches [23–25].
The Department of Health CR Commissioning Pack [16]
and recent British Association for Cardiovascular
Prevention and Rehabilitation guidelines [23] recommend
that the choice of home-based CR as an alternative to
centre-based programmes should be provided to all
patients as part of a menu-based approach.
Randomised controlled trials showed no differences
between home-based and centre-based programmes
concerning mortality, cardiac events, exercise capacity,
smoking cessation, blood pressure, total cholesterol,
anxiety and depression, and health-related quality of
life [20, 26–28]. However, adherence to treatment in
home-based programmes was superior [26].
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Recent UK CR data [29] demonstrated that 28% of pa-
tients experience symptoms of anxiety within the clinical
range at the start of CR and only 6% move into the normal
anxiety range after CR; however, the variation of improve-
ment at the local level ranges from − 9% (some patients
get worse) to 28%. A further 19% of patients report symp-
toms of depression at the beginning of CR and only 6%
move into the normal depression category following CR,
with the variation of improvement at the local level ran-
ging from − 8% to 24%. Thus, most patients continue to
experience anxiety and depression symptoms within the
clinical range after completing CR programmes. Conse-
quently, it is imperative that effective interventions for
anxiety and depression are integrated into both
centre-based and home-based CR programmes.
There is a need to improve the treatment of anxiety
and depression in CR. In contrast, treatment in mental
health settings has been improving. There is strong evi-
dence supporting the effectiveness of metacognitive ther-
apy (MCT) [30], a new psychological therapy that could
offer a potentially effective intervention for treating de-
pression and anxiety in patients attending CR pro-
grammes. MCT is founded on an evidenced-based
model called the Self-Regulatory Executive Function
model [31, 32], which proposes that emotional distress is
maintained by a style of thinking called the cognitive at-
tentional syndrome (CAS). The CAS is characterised by
repetitive negative thinking (worry and/or rumination),
focusing attention on threat (e.g. thoughts, physical
symptoms, emotions), and maladaptive coping strategies
(e.g. cognitive avoidance, behavioural avoidance, alcohol/
substance misuse). This thinking style is driven by
underlying metacognitive beliefs, which lead to pro-
longed negative processing and maintenance of psycho-
logical distress. Metacognitive beliefs can be divided into
positive beliefs that focus on the usefulness of worry, ru-
mination, threat monitoring and other coping strategies
(e.g. avoidance), for example, “Worrying helps me to
avoid problems in the future”. Negative metacognitive
beliefs, on the other hand, focus on the uncontrollability,
danger, importance and meaning of thoughts, such as
“My worrying thoughts persist, no matter how I try to
stop them”. In the Self-Regulatory Executive Function
model, the CAS and metacognitive beliefs are transdiag-
nostic, meaning that they maintain all forms of emo-
tional disorder. There is evidence supporting the role of
these factors in emotional distress across a wide range of
health conditions including cancer [33], Parkinson’s dis-
ease [34, 35] and chronic fatigue syndrome [36, 37]. In
addition, a recent systematic review demonstrated that
unhelpful styles of thinking (worry and/or rumination)
predicted depression, anxiety and emotional distress in
people with a range of long-term health conditions in-
cluding heart disease [38].
Randomised controlled trials have shown that MCT is
an effective psychological treatment for anxiety and de-
pression [39–41]. In addition, MCT has been identified
as a high intensity psychological intervention for treating
individuals with a diagnosis of generalised anxiety dis-
order by the National Institute for Health and Care Ex-
cellence [42]. In a recent meta-analysis of the efficacy of
MCT for anxiety and depression it was found to be more
effective than waitlist control groups and cognitive be-
havioural therapy [43].
In summary, MCT offers an effective psychological ap-
proach to treating anxiety and depression in mental
health settings and there is preliminary evidence of
MCT effectiveness across a range of medical conditions
(i.e. cancer, Parkinson’s disease and chronic fatigue syn-
drome). As MCT is based on the transdiagnostic pro-
cesses underlying psychological distress, it could be that
it has the potential to generalise well to heart disease pa-
tients attending CR programmes who suffer from anx-
iety and depression. Therefore, the PATHWAY
programme aims to provide evidence of MCT integrated
into CR services investigating MCT in two formats as a
centre-based group intervention (Group-MCT) and a
home-based self-help intervention (Home-MCT). The
Group-MCT intervention has been described in Wells et
al. [44] and the Home-MCT intervention is described in
the present article. Such treatment options are in line
with a modern era menu-based approach and could add
to the delivery of CR programmes by increasing the
range of options for accessing psychological support that
do not require referral to mental health services.
Aims
There is currently no evidence on MCT delivered in a
home-based self-help format among patients referred to
CR services. Therefore, the aims of the PATHWAY
Home-MCT trial are to (1) evaluate the acceptability of
the Home-MCT intervention to CR patients and con-
duct a feasibility trial of Home-MCT plus usual CR
compared to usual CR; (2) collect data on patient vari-
ables and outcome measures (e.g. emotional distress,
post-traumatic stress, metacognitive beliefs, quality of
life) to inform the design and sample size for a full-scale
trial; (3) establish provisional evidence of the effective-
ness of Home-MCT at reducing anxiety and depression
symptoms; (4) obtain qualitative data to help refine the
presentation and delivery of Home-MCT for a full-scale




The PATHWAY Home-MCT is a single-blind feasibility
randomised controlled trial with 4- and 12-month
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follow-up comparing Home-MCT alongside usual CR
(intervention) versus usual CR (control). Qualitative and
economic evaluations will be embedded within the trial.
Figure 1 shows an overview of the trial design according
to the CONSORT guidelines [45]. The Recommenda-
tions for Interventional Trials 2013 (SPIRIT) Checklist
[46, 47] is included in Additional file 1. Figure 2 shows a
schedule of enrolment, interventions and assessments.
Study setting
This feasibility trial is part of a 5-year programme of re-
search funded by the National Institute for Health Re-
search and sponsored by Greater Manchester Mental
Health NHS Foundation Trust (GMMH). The study will
take place in England, at NHS sites offering CR.
Trial population
The trial population are heart disease patients referred
to CR programmes at two NHS sites in England, the
Aintree University Hospitals NHS Foundation Trust and
Bolton NHS Foundation Trust.
Eligibility criteria
Patients will be invited to take part in the trial if they
meet the following inclusion criteria:
(1) Meets Department of Health and/or British
Association for Cardiovascular Prevention and
Rehabilitation CR eligibility criteria. Thus, the patient
will have at least one of the following: acute coronary
syndrome, revascularisation, stable heart failure,
stable angina, implantation of cardioverter
defibrillators/cardiac resynchronisation devices, heart
valve repair/replacement, heart transplantation and
ventricular assist devices, adult congenital heart
disease, other atypical heart presentation.
(2) A score of ≥ 8 on the anxiety and/or depression
subscales of the Hospital Anxiety and Depression
Scale (screening HADS) [48].
(3) Minimum of 18 years old.
(4) A competent level of English language skills (able
to read, understand and complete questionnaires
in English).
Fig. 1 CONSORT 2010 Standard Randomised Control Trials flow diagram (numbers are target values)
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Participants will be excluded if they meet any of the
following criteria:
(1) Cognitive impairment which precludes informed
consent or ability to participate.
(2) Acute suicidality.
(3) Active psychotic disorders (i.e. two (or more) of the
following: delusions, hallucinations, disorganised
speech, grossly disorganised or catatonic behaviour,
negative symptoms).
(4) Current drug/alcohol abuse (a maladaptive pattern
of drinking, leading to clinically significant
impairment or distress).
(5) Concurrent psychological intervention for
emotional distress that is not part of usual care.
(6) Antidepressant or anxiolytic medications initiated in
the previous 8 weeks.
(7) Life expectancy of less than 12 months.
Patients who are ineligible or decline to participate will
continue to receive care along the usual CR pathway.
Recruitment and allocation
Patients referred to the CR programme at each site will
complete the HADS [48] as part of their routine
assessments. If a patient scores 8 or above on the anxiety
and/or the depression subscale of the screening HADS,
CR nurses will screen the patient’s medical notes to
check for eligibility. Patients deemed eligible for the trial
will be provided with information about the study (i.e.
invitation flyer and participant information sheet) and
CR staff will seek an expression of interest either
face-to-face or by telephone.
Interested eligible patients will be contacted by a re-
search assistant, who will arrange to meet with them
prior to their first CR session at a convenient location
(i.e. NHS Trusts or patients’ home). A research assistant
or person designated by the principal investigator at
each hospital site will take written informed consent.
Baseline questionnaires will be collected face-to-face or
over the phone and will be administered prior to the
participant’s first CR session. The completion of the
questionnaires will take between 35 and 45 minutes.
After consent and baseline assessments, participants will
be randomised via telephone/email link to the Centre
for Biostatistics at the University of Manchester. A ran-
domisation sequence will be created using Stata 14 stat-
istical software [49], stratified by sex, site and screening
HADS scores [48]. Participants will be allocated to trial
arms in a 1:1 allocation using randomised block sizes of
Fig. 2 Schedule of enrolment, interventions and assessments. CR cardiac rehabilitation, TAU treatment as usual, Home-MCT home-based
metacognitive therapy, HADS Hospital Anxiety and Depression Scale, MCQ-30 Metacognitions Questionnaire 30, CAS-1R Cognitive Attentional
Syndrome Scale-1 Revised, IES-R Impact of Event Scale-Revised, EQ-5D European Quality of Life 5 Dimensions, EPQ Economic Patient
Questionnaire. *Intervention participants only
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4 and 6. Research assistants who are not blind to treat-
ment allocation will inform each participant of their
group allocation. Research assistants who are collecting
assessment data (i.e. baseline, 4 and 12 months
post-randomisation) will be blind to treatment alloca-
tion, as will the chief investigator (AW) and the trial
statistician (DR).
Trial conditions
Usual CR (control group)
Participants in the control group will be invited to join
the usual CR programme offered at their site. The ma-
jority of patients at both sites will attend group-based
programmes that include exercise and educational ses-
sions. The exercise sessions will include warm up exer-
cises, a circuit of cardiovascular exercises at the
appropriate intensity for each patient, cool down and
stretching exercises. The educational sessions will cover
risk factors that contribute to heart problems, signs,
symptoms and medication, the importance of eating
healthily and exercising, and a one-off talk about stress
(e.g. signs, symptoms and relaxation techniques). Partici-
pants will be offered weekly sessions over a period of 6–
8 weeks and each session will last approximately 2 hours.
A small number of patients at each site will receive
home-based CR, which comprises similar components
to the group programme tailored to participants’ individ-
ual needs. The study sites will offer additional support to
participants experiencing anxiety and/or depressive
symptoms based on CR staff ’s clinical judgement of
need; Aintree University Hospitals NHS Foundation
Trust will offer a 1-hour occupational therapy appoint-
ment and Bolton NHS Foundation Trust will offer indi-
vidual counselling. Furthermore, patients who are found
to have particularly high levels of depression or anxiety
will be referred to their GP.
Home-MCT alongside usual CR (intervention group)
The intervention group will receive Home-MCT in
addition to the usual CR.
Home-MCT consists of a self-help manual comprising
six modules. Members of the PATHWAY programme’s
service user advisory group provided feedback on the
structure and user-friendliness of the Home-MCT man-
ual. Suggested changes were implemented before com-
mencing recruitment to the trial.
Participants will complete the Home-MCT manual at
their own pace over 6–8 weeks. It is anticipated that par-
ticipants will complete one module per week, but flexibil-
ity in rate of progress will be permitted. The Home-MCT
modules focus on modifying the specific metacognitive
beliefs and processes that maintain anxiety and depres-
sion. Modules comprise well-specified techniques for
developing new strategies to overcome worry and
rumination, and modifying the metacognitive beliefs that
maintain unhelpful patterns of thinking. Participants will
be instructed to practise the techniques introduced in
each module and to complete tasks between modules.
Participants will receive three scripted telephone calls
(up to 30 minutes each) from trained CR staff (e.g.
nurses, occupational therapists) over the course of the
intervention. The first telephone call will provide an
overview of the Home-MCT manual and the remaining
two will offer support and guidance on completing the
modules and implementing Home-MCT strategies. The
first telephone call will be delivered before the partici-
pant starts the manual and the remaining ones after the
completion of modules 2 and 4. The CR staff will be
asked to follow a structured script when making tele-
phone contact. Their role is to provide support and
guidance on completing Home-MCT.
CR staff training and supervision for the implementation of
scripted telephone calls
At least two members of each CR team will be specific-
ally trained to deliver the telephone support calls. Train-
ing will consist of two full-day workshops to enable the
CR practitioners to become familiar with the implemen-
tation of, and to role-play, the telephone scripts. CR staff
will have basic knowledge of the metacognitive model;
however, they will not be skilled in the delivery of MCT
and will not be required to deliver MCT.
Telephone calls provided by CR staff will be
audio-recorded and transcribed if a participant has given
their written informed consent to ensure consistency of
delivery of the support across sites and to examine ad-
herence to the telephone script.
Data collection: Participant timeline
Participants will complete assessments at three time-points,
namely baseline (pre-CR), 4-months post-randomisation
and 12-months post-randomisation (Fig. 1).
To minimise attrition rates, participants will be offered
a number of options for completing follow-up measures,
including postal return, online, by telephone or
face-to-face (at NHS sites or participants’ homes). The
participant’s time involvement in the study is 12 months.
Participants will be compensated for completing each
assessment, receiving a £5 voucher at baseline and a £10
voucher at the 4- and 12-month follow-ups.
Criteria for discontinuation of participants
Participants may withdraw from the study at any time
without giving a reason and without any consequences
to themselves, their healthcare or their ability to take
part in future research. Participants who withdraw will
continue to receive usual care. Participants can also be
withdrawn at the request of the Chief Investigator, but
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this would only happen if a participant’s life or
long-term health or welfare is at risk from continued
participation in the study.
Outcomes
The principal outcomes are acceptability and feasibility. Ac-
ceptability of the Home-MCT intervention will be assessed
primarily using a set of three participant self-report ques-
tionnaires relating to credibility, user-friendliness and ad-
herence to the intervention, as described below. The
feasibility of conducting a full trial will be evaluated princi-
pally in terms of the ability to recruit and retain partici-
pants and to collect high quality complete data on the
required measures across the timeline of the study.
Measures
Credibility questionnaire
The credibility of the intervention has been defined as
(1) how logical Home-MCT seems to participants, (2)
how successful Home-MCT seems in reducing levels of
emotional distress, and (3) how confident the partici-
pants feel in recommending this intervention to some-
one experiencing similar problems. The Credibility
Questionnaire includes three questions assessing these
dimensions, with each rated using a scale from 0 to 100.
The measure has been adapted from the Credibility/Ex-
pectancy Questionnaire developed by Devilly and Borko-
vec [50]. The Credibility Questionnaire aims to assess
how believable, logical and compelling the intervention
is to the participant, rather than post-intervention satis-
faction or effectiveness. For this purpose, this question-
naire will be completed after reading the introduction
section of the Home-MCT manual and before starting
module 1.
Adherence and User-Friendliness Questionnaire
The Adherence and User-Friendliness Questionnaire
was developed for this study and includes six questions
that assess how many modules were completed (ranging
from 0 to 6), how accessible, easy to follow, easy to
understand and easy to use the Home-MCT manual is,
and how much the participant needed the supportive
telephone calls. All questions, except for the number of
modules completed, are rated on a scale from 0 to 100.
This questionnaire will be completed at the end of the
intervention, with the time-frame for returning this
questionnaire being up to 4-months post-randomisation.
Exit Questionnaire
The Exit Questionnaire includes two questions to collect
specific details about the intervention, namely (1)
“Which modules from the Home-MCT manual have
you completed?” and (2) “How much time have you
spent to complete each module?” This questionnaire will
be completed at the end of the intervention, with the
time-frame for returning this questionnaire being up to
4-months post-randomisation.
The following self-report questionnaires will also be
completed by all participants at each assessment point
(i.e. baseline, 4 months follow-up and 12 months
follow-up) to assess symptoms, psychological mecha-
nisms and healthcare use.
Hospital anxiety and depression scale (HADS) [48]
The HADS is a 14-item self-report scale assessing anx-
iety (7 items) and depression (7 items). Respondents rate
their emotional distress based on the past 7 days using a
4-point scale (from 0 to 3). Possible scores for each
sub-scale range from 0 to 21. Scores from 0 to 7 are
categorised as normal, from 8 to 10 mild, from 11 to 14
moderate, and from 15 to 21 severe [47]. The HADS is
routinely used in CR [28], and has shown good internal
consistency for both subscales (i.e. Cronbach’s alpha,
anxiety = 0.85, depression = 0.80, total scale = 0.89) [51].
Impact of Events Scale – Revised (IES-R) [52]
The IES-R is a 22-item self-report measure that as-
sesses subjective distress caused by traumatic events.
For this study, participants will be instructed to answer
the items with respect to their recent heart event. Re-
spondents rate the items based on the past 7 days using
a 5-point scale ranging from 0 (not at all) to 4 (ex-
tremely). This scale yields a total score ranging from 0
to 88 and three subscale scores: Intrusions, Avoidance
and Hyperarousal. Scores of 24 to 32 indicate
post-traumatic stress disorder is a clinical concern,
whereas scores of 33 to 88 indicate a diagnosis of
post-traumatic stress disorder [52]. The IES-R subscales
have good internal consistency (Cronbach’s alphas
range from 0.79 to 0.91) [52].
Metacognitions Questionnaire 30 (MCQ-30) [53]
The MCQ-30 is a 30-item self-report scale that mea-
sures five different domains of metacognition (cognitive
confidence, positive beliefs about worry, cognitive
self-consciousness, negative beliefs about uncontrollabil-
ity and danger, need to control thoughts). Respondents
rate how much they “generally agree or disagree” with
the statements presented on a 4-point scale (1, do not
agree; 2, agree slightly; 3, agree moderately; 4, agree very
much). This questionnaire yields a total score ranging
from 30 to 120 and four subscale scores. High scores in-
dicate, respectively, lack of cognitive confidence, more
positive or negative beliefs about worry, increased ten-
dency towards cognitive self-consciousness, and greater
belief in the need to control thoughts. The MCQ-30
subscales have good internal consistency (Cronbach’s al-
phas range from 0.72 to 0.93) [53–55].
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European Quality of Life 5 Dimensions 5 Levels (EQ-5D-5 L)
[56, 57]
The ED-5D-5 L is a standardised questionnaire for use
as a measure of health status and its use is recom-
mended in the National Institute for Health and Clinical
Excellence guidelines for economic evaluation [58]. The
tool assesses five health dimensions: mobility, self-care,
usual activities, pain/discomfort and anxiety/depression.
Each dimension has five response options: no problems,
slight problems, moderate problems, severe problems
and extreme problems. In addition, respondents also rate
their overall health on a 0–100 vertical visual analogue
scale. The measure has been shown to be valid and reli-
able in a cardiovascular population [59].
Economic Patient Questionnaire (EPQ)
The EPQ is designed to collect data on outpatient ser-
vices and non-hospital-based health and social care use.
The EPQ assesses three areas, namely use of primary
and community-based health services, social support
services accessed outside the hospital, and aids and
equipment used as part of care.
Cognitive Attentional Syndrome Scale-1 revised (CAS-1R)
The CAS-1R has been adapted for the present study
from the original Cognitive Attentional Syndrome
Scale-1 [30], a 16-item self-report questionnaire asses-
sing an individual’s metacognitive beliefs, knowledge and
strategies. The CAS-1R includes 10-items assessing the
degree to which individuals have been worrying and/or
focusing attention on threats, the degree to which indi-
viduals hold negative metacognitive beliefs about worry
and the degree to which individuals hold positive meta-
cognitive beliefs about worry. Each CAS-1R item is
scored on a scale from 0 to 100 with higher scores indi-
cating more use of unhelpful metacognitive strategies or
greater conviction in metacognitive beliefs.
Sociodemographic and clinical data questionnaire
This questionnaire is designed to collect sociodemo-
graphic information and clinical data. Sociodemographic
information will be collected only at baseline and includes
age, sex, ethnicity, marital status, living arrangements, em-
ployment status and educational attainment. Clinical data
to be collected at each time-point includes height, weight,
smoking status, alcohol use, cardiovascular events, other
health conditions, and details about medications for anx-
iety, depression and psychological therapies.
In addition to the measures included above, CR staff
will complete a CR register for each participant detailing
the number of exercise sessions and educational talks
attended. The CR register will provide details to assess
adherence to usual CR. Adherence to CR has been de-
fined as the attendance to four or more sessions to each
component of usual CR (exercise sessions and educa-
tional talks).
Qualitative evaluation
Participants allocated to the intervention group will be
interviewed, including those who complete the interven-
tion, those who only complete part of it, and those who
do not engage with any part of the intervention. Partici-
pants will be sampled purposively to include ranges of
age and psychological distress, and levels of participa-
tion. Sampling will stop when theoretical saturation is
reached. In semi-structured interviews, participants will
be prompted to talk about (1) their emotional experience
since the index event, (2) their reactions and expecta-
tions on being offered the intervention and (3) their ex-
perience of undertaking it.
Interviews will be semi-structured and conversational
in style, and an interview guide will be used. Interviews
will be conducted by telephone or face-to-face, as pre-
ferred by each participant, audio-recorded, transcribed
verbatim and anonymised for analysis.
Sample size calculation
The sample size is based on having sufficient numbers
of participants to evaluate acceptability and feasibility,
and to obtain provisional evidence for effectiveness. To
these ends, the aim is to recruit 108 participants in total.
Anticipating a 25% attrition rate, this will provide a final
n = 40 in each arm, i.e. a total of 80 participants. With
this sample, overall recruitment and retention rates for a
full-scale trial will be estimated with an error of plus/
minus 8% at most. This sample is also more than ad-
equate for estimation of variability in outcome measures
for which samples of 40 are generally sufficient [60].
Based on our experience of previous phases of the
PATHWAY programme, 10.5 patients have been re-
cruited for every 100 referrals, over 12 months, across
three different sites. Following this figure and based on
the number of annual referrals provided by the two
participating sites on this phase of the PATHWAY
programme, we estimate recruiting 8–9 patients per
month, across both sites, over 12 months.
Feasibility trials are not powered to provide a definitive
effectiveness analysis [59]. Therefore, evaluation of ef-
fectiveness will focus on effect size estimates and confi-
dence intervals rather than statistical significance.
Analyses
The trial will be analysed using quantitative, qualitative
and economic methods.
Quantitative analysis
To assess acceptability of Home-MCT, descriptive statis-
tics will be used to evaluate participant ratings on the
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credibility, adherence and user-friendliness questionnaires,
along with rates of completion of the first four modules of
the Home-MCT manual. The ability to recruit and retain
participants will be indicated by monthly rates of eligible
patients consenting to participate and arm-specific attri-
tion rates at 4- and 12-months follow-up.
An estimate of treatment effect size will be derived by
comparing the control and intervention groups on meta-
cognitive beliefs (MCQ-30 Positive Beliefs and Negative
Beliefs subscales), CAS-1R and HADS total score at 4-
and 12-months follow up, controlling for respective
baseline and other relevant covariates. The analyses will
use intention-to-treat principles and complete cases
only, under a multivariable linear regression model.
Analysis of variability and performance of the outcome
measures, coupled with recruitment and attrition rates,
will be used to estimate the sample size for a full-scale
RCT, including the number of sites and participants
required.
All analyses will be overseen and directed by the trial
statistician (DR), who will remain blind to group alloca-
tion throughout.
Qualitative analyses
Analysis will draw on a pluralist qualitative approach.
Data will be considered descriptively at first, informed
by grounded theory principles [61]. We will take a more
interpretative approach as analysis proceeds, going be-
yond line-by-line analysis to examine data in the context
of the entire interview, the participant’s clinical context
and the emerging analysis, and attending both to what is
present and noticeably absent. Analysis will draw on
constant comparison, as we iterate between the develop-
ing analysis and new interviews, and revisit earlier inter-
views in light of new analytic turns.
Analysis will be developed and tested by regular dis-
cussion among a core analytic team comprising a soci-
ologist (RM) and clinical psychologists with expertise in
qualitative methods (PS) and MCT (PF), and referred
periodically to the broader study team. The core team
will read all transcripts, and the broader team will read
selected data. The framework of MCT will not be used
to shape the analysis, but we will relate the final analysis
to the theory of MCT that underlies the intervention.
The main product of the analysis will be an understand-
ing of contextual and intervention-related factors that
promote or impair take-up of the intervention or that
influence its benefits.
Economic analysis
The economic analysis will explore the potential of
Home-MCT to be cost-effective to provide a preliminary
estimate of cost-effectiveness and inform the design of
future evaluations. A cost-effectiveness acceptability
analysis will be conducted from the perspectives of
health and social care providers and patients, the key
stakeholders in treatment decisions. The time horizon
for the primary economic analysis will be at 12-month
follow-up.
The primary measure of health benefit is Quality
Adjusted Life Years, which will be estimated from the
EQ-5D-5 L [56, 57] and the utility tariffs recommended
by NICE at the time of the analysis [58]. At the end of
the trial, a data request will be submitted to NHS
Digital to obtain data on hospital-based service use
covering all assessment points (baseline, 4- and
12-month follow-up). To supplement these data, the
EPQ will be used at baseline, 4- and 12-month
follow-up. Each item of resource use will be multi-
plied by the unit cost specific to that item. Standard
national unit costs will be used. Single imputation
will be used to impute missing baseline values for
costs, utility and key covariates. Multiple imputation
will be used to impute missing observations from par-
ticipants who complete follow-up, and missing
follow-up data for participants lost to follow-up.
The primary and sensitivity economic analyses will
control for key baseline covariates or characteristics
identified in the study. Cost-effectiveness acceptability
curves will assess the likely cost effectiveness of the
intervention and uncertainty in the observed data. This
approach re-values outcomes in monetary terms. How-
ever, in the UK, there is no universally agreed monetary
value for the types of outcome measures used in cost ef-
fectiveness analyses. An approach used in healthcare is
to ask the question: what is the maximum amount
decision-makers are willing to pay to gain one unit of
outcome? An analysis of decisions made by NICE sug-
gests a range of implicit values between £15,000 and
£30,000 for the amount a decision-maker is prepared to
pay to gain one Quality Adjusted Life Year. This hypo-
thetical threshold willingness-to-pay values will be used
to estimate the probability that an intervention is
cost-effective.
Sensitivity analysis will assess uncertainty due to de-
sign decisions. Within trial analyses include using a
4-month time horizon, varying the assumptions and
components used to estimate the unit cost of
Home-MCT and using alternative measures of health
benefit (primary and key secondary clinical outcomes).
In addition, decision modelling will be used to extrapo-
late over longer time horizons of 2 and 5 years.
Trial management and oversight arrangements
This trial is part of a larger research programme funded
by the National Institute of Health Research under its
Programme Grants for Applied Research scheme
(RP-PG-1211 20,011). The programme is overseen by an
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independent programme steering committee which meets
every 6 months to provide expert advice, supervise the
overall programme on behalf of the National Institute for
Health Research and the sponsor, and monitor progress
against agreed milestones. A programme executive com-
mittee comprising the chief investigator, co-investigators,
the core project team and other relevant parties meets
quarterly. Notwithstanding the legal obligations of the
sponsor and chief investigator, the executive committee
has operational responsibility for the conduct of the trial,
including monitoring overall progress to ensure adherence
to the protocol and for taking appropriate action to
safeguard participants and the quality of the trial. A
programme management group comprising the chief
investigator and core project team meet weekly to over-
see the day-to-day management of the programme.
There is also a service user advisory group which meets
at least every 6 months and provides advice and feed-
back on a range of trial-related activities, e.g. reviewing
study documents.
Data management
Participants will be randomly allocated a study identity
code number for use on all study documents. The re-
search team will create a confidential database of each
participant’s name, date of birth and study identity code
to permit identification of participants enrolled in the
study, e.g. for follow-up. All study documents will be
held in strictest confidence and access to study docu-
ments will be restricted to authorised persons. Partici-
pant consent forms will be filed in the corresponding
site file and in participants’ medical notes. Baseline and
follow-up data, which is anonymous data, will be stored
in locked filing cabinets at GMMH. These data will be
entered into an electronic database for analysis pur-
poses by study team members blind to trial arm alloca-
tion. All computers are password protected and adhere
to the secure storage policies of the NHS trust and
University of Manchester.
Ten percent of the data entered electronically from
each of the three time points (baseline, 4- and
12-months follow-up) will be selected at random and
quality checks will be performed by the statistical team.
Any discrepancies will be noted, corrected and counted
to obtain an error rate. Depending on the error rate, fur-
ther checks will be performed.
Safety reporting
Plans and procedures are in place for negative changes
in participants’ psychological state. Health professionals
delivering the Home-MCT scripted telephone calls will
monitor any potential adverse events (AEs) or serious
adverse events (SAEs) over the time of the intervention.
Two hypothesised AEs that might occur due to the
Home-MCT intervention are lowered mood and suicid-
ality as a result of discussing current health status, redu-
cing or terminating usual treatment in the event that a
patient finds Home-MCT particularly helpful. Although
it is acknowledged that thinking or talking about distress
can worsen mood, this is rare and usually transient. Any
AEs will be recorded at the study site using an AE form,
which will be completed by the health professionals.
These will be reported to the research team and
reviewed for seriousness and causality by a designated
sub-investigator who is not blind to treatment allocation.
Any that are deemed SAEs, and are related to the inter-
vention, will be reported to the ethics committee, the
programme steering committee and the sponsor’s Re-
search and Innovation Manager within 7 days of the
event. AEs and SAEs will be reviewed on a quarterly
basis at the programme’s executive committee meetings.
Dissemination and publication policy
The main study results will be published in peer-reviewed
journals and these will be made freely available online
wherever possible. All presentations and publications re-
lating to the study must be authorised by the Chief Inves-
tigator and the sponsor. Authorship of any secondary
publications resulting from the study will reflect the intel-
lectual and time input into these studies. No investigator
may present or attempt to publish data relating to the
PATHWAY study without prior permission from the Chief
Investigator and the sponsor. The findings will also be
presented at national, international and regional confer-
ences and in public involvement events where the infor-
mation from this study is relevant.
Discussion
Forty-five percent of patients referred to CR report clin-
ically significant levels of anxiety or depression, and
most patients continue to experience these symptoms
after completing CR programmes [28]. Symptoms of
anxiety and depression have been associated with re-
duced adherence to CR programmes, reduced quality of
life, increased risk of further cardiovascular events,
greater health services costs, and an increased risk of
mortality [3, 7–12, 14, 15]. It has been demonstrated
that MCT is highly effective at reducing symptoms of
anxiety and depression in mental health settings [42].
The integration of MCT delivered in a home-based
self-help format into the CR programme has the poten-
tial to improve psychological, physical and economic
outcomes for patients. The present study will provide
data on the acceptability of the Home-MCT self-help
intervention plus feasibility trial data to inform the de-
sign and sample-size for a full-scale trial. In addition,
qualitative data will be obtained to understand the bar-
riers and enablers to Home-MCT, and participants’
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experiences of the intervention. Provisional estimates
will also be made of the treatment effect size associated
with Home-MCT, and whether it is potentially a
cost-effective intervention, together with appropriate
measures of uncertainty reflecting the limited ability of
the study to measure these accurately.
Trial status
The first participant was randomised to the PATHWAY
Home-MCT trial on April 20, 2017. Recruitment is pre-
dicted to continue until April 2018.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Intervention Trials (SPIRIT) Checklist. (DOC 120 kb)
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